Ganciclovir for injection

(1) Ganciclovir belongs to the guanine class of antiviral drugs. (2) This product is a homologue of acyclovir, but has a stronger effect, especially against cytomegalovirus in AIDS patients. After entering the cell, this product is rapidly phosphorylated to form a monophosphate compound, which is then converted into a triphosphate compound by the action of cellular kinase. The phosphorylation process of this drug in cells infected with cytomegalovirus is faster than that in normal cells. The triphosphate of this drug can competitively inhibit DNA polymerase and is incorporated into the DNA of viruses and host cells, thereby inhibiting DNA synthesis. This drug has a stronger inhibitory effect on viral DNA polymerase than on host cell DNA polymerase.

Ganciclovir. Its chemical name is: 9-(1,3-diopyridine-2-propoxymethyl)-guanine.

This product is white powder or loose lumps.

(1) It is suitable for the induction and maintenance treatment of cytomegalovirus retinitis in immunocompromised patients (including AIDS patients). (2) It can also be used to prevent cytomegalovirus infection in patients receiving organ transplants and to prevent cytomegalovirus disease in AIDS patients with positive cytomegalovirus serological tests.

1. Induction period: intravenous drip of 5 mg/kg per body weight, once every 12 hours, each drip for more than 1 hour, the course of treatment is 14 to 21 days, and the dose should be reduced for patients with renal impairment. When the creatinine clearance rate is 50-69 ml/min, intravenous drip of 2.5 mg/kg every 12 hours; when the creatinine clearance rate is 25-49 ml/min, intravenous drip of 2.5 mg/kg every 24 hours; when the creatinine clearance rate is 10-24 ml/min, intravenous drip of 1.25 mg/kg every 24 hours; when the creatinine clearance rate is less than 10 ml/min, the drug is given 3 times a week, each time 1.25 mg/kg is given after hemodialysis. 2. Maintenance period: intravenous drip of 5 mg/kg per body weight, once a day, intravenous drip for more than 1 hour. For patients with renal impairment, the dose should be adjusted according to the creatinine clearance rate: when the creatinine clearance rate is 50-69 ml/min, intravenous drip of 2.5 mg/ every 24 hours kg; when the creatinine clearance rate is 25-49 ml/min, intravenous drip of 1.25 mg/kg every 24 hours; when the creatinine clearance rate is 10-24 ml/min, intravenous drip of 0.625 mg/kg every 24 hours; when the creatinine clearance rate is <10 ml/min, give 3 times a week, each time 0.625 mg/kg after hemodialysis. 3. Preventive medication: intravenous drip of 5 mg/kg per body weight, the drip time is at least 1 hour, once every 12 hours, for 7 consecutive days; followed by 5 mg/Kg, once a day, for a total of 7 days. When the product is intravenously dripped, the preparation method is as follows: first determine the dosage according to the patient's weight, dissolve it with an appropriate amount of water for injection or sodium chloride injection, and then inject it into 100 ml of sodium chloride injection, 5% glucose injection, compound sodium chloride injection or compound sodium lactate injection. The concentration of the drip solution shall not be greater than 10 mg/ml

1 If you feel unwell while taking this product, tell your doctor or pharmacist as soon as possible. If the situation is urgent, stop taking the medicine first. 2 If the medicine is used properly, this medicine can bring you satisfactory therapeutic effects. It may also cause some adverse reactions, but not everyone will experience them. You may not encounter any of them, so don't be nervous. The following are the possible adverse reactions of ganciclovir: (1) The most common adverse reaction is bone marrow suppression. After taking the medicine, about 40% of patients have a neutrophil count reduced to less than 1000/mm3, and about 20% of patients have a platelet count reduced to less than 50,000/mm3. In addition, anemia may occur. (2) Central nervous system symptoms such as mental abnormalities, tension, tremors, etc., with an incidence of about 5%, and occasionally coma, convulsions, etc. are rare. (3) Skin rash, itching, drug fever, headache, dizziness, dyspnea, nausea, vomiting, abdominal pain, loss of appetite, abnormal liver function, gastrointestinal bleeding, arrhythmia, increased or decreased blood pressure, hematuria, increased blood urea nitrogen, hair loss, decreased blood sugar, edema, general discomfort, increased creatinine, and eosinophilia may occur. Rare.

(1) Do not stop taking this product or reduce the dosage without consulting a physician. (2) This product is contraindicated for those who are allergic to it or acyclovir.

(1) If you take any other medicines, please inform your doctor or pharmacist, including any over-the-counter medicines purchased from a pharmacy, supermarket or health food store. These medicines may be affected by this product, or this product may affect the efficacy of other medicines. You may need different doses or need to take different medicines. Please follow your doctor's advice. (2) Doctors and pharmacists may have more information on precautions when taking this product. (3) Some medicines (or foods) may interfere with this product, including: ① When drugs that affect the hematopoietic system, bone marrow suppressants and radiotherapy are used with this product, the inhibitory effect on the bone marrow may be enhanced. ② When this product is used with nephrotoxic drugs (such as amphotericin B and cyclosporine), it may enhance renal damage, reduce the renal excretion of this product and cause toxic reactions. ③ When used with zidovudine, it can enhance the toxicity to the hematopoietic system and must be used with caution. ④ When used with didanosine or used sequentially, the area under the drug-time curve of the latter can be significantly increased (increased by 72% to 111%), and the renal clearance of both remains unchanged. ⑤ The use of this product with imipenem-cilastatin may cause systemic convulsions. ⑥ The combined use of this product with probenecid or drugs that inhibit renal tubular secretion can reduce the renal clearance of this product by about 22%, and increase its area under the drug-time curve by about 53%, thus easily causing toxic reactions. ⑦ Avoid using it with dapsone, pentamidine, flucytosine, vinblastine, doxorubicin, trimethoprim, sulfonamides and nucleoside drugs.

Keep tightly closed in a cool, dry place.

0.25g

Wuhan Pusheng Pharmaceutical Co., Ltd.

• Founded in:

  1998-05-11

• Address:

  No. 1, Miaoshan Sunshine Avenue, Jiangxia District, Wuhan

• Tax NO.:

  91420000707090425F

• Registered Funds:

  23.141141 million yuan

• Email:

  Log in to view